Latest TroVax Stories
SAN CARLOS, Calif., June 24 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that the first patients have been dosed in a new Phase 1 dose-escalation clinical study to evaluate NKTR-102, the company's lead oncology compound, in combination with 5-fluorouracil (5-FU)/leucovorin in refractory solid tumor cancers.
BETHESDA, Md., June 7 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ("NWBT") (OTC Bulletin Board: NWBO), developer of the DCVaxÂ® personalized cancer vaccine, today announced the release of a new detailed report by Pharmaceuticals and Biotech Analyst Dr.
NEW YORK, June 5 /PRNewswire-FirstCall/ -- Delcath Systems, Inc.
Patients with stage III colon cancer treated with 5-FU-based chemotherapy after complete surgical removal of their tumor after 1995 had improved overall survival with no change in time to recurrence compared to patients treated before 1995.
Small but decisive study highlights differences in clear- and non-clear cell subtypes.
COLUMBIA, Md., May 13 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN) announced today that after reviewing data from 294 patients including data from 12 Japanese patients enrolled in the pivotal Phase III ThermoDoxÂ® clinical study (HEAT Study) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to enroll patients in the trial.
COLUMBIA, Md., April 15 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN) today announced that Dr. Ronnie T.P.
COLUMBIA, Md., April 12 /PRNewswire/ -- Celsion Corporation (Nasdaq: CLSN) today announced that Dr. Ronnie T.P.
Leukemia related protein 16 (LRP16) gene is an important estrogen-responsive gene.
CALGARY, March 9 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
- To fire mitraille at.